Synthesis of homogenous glycans in quantitative yields represents a major bottleneck to the 2 production of molecular tools for glycoscience, such as glycan microarrays, affinity resins, and 3 reference standards. Here, we describe a combined biological/enzymatic method termed 4 bioenzymatic synthesis that is capable of efficiently converting microbially-derived precursor 5 oligosaccharides into structurally uniform human-type N-glycans. Unlike starting material 6 obtained by chemical synthesis or direct isolation from natural sources, which can be time 7
Introduction 1
Carbohydrate chains, known as glycans, represent a vast source of biological diversity across 2 all domains of life. They play a key role in almost every aspect of normal physiology, as well as in 3 the etiology of nearly every major disease (Varki, 1993) . Approximately 1% of the human genome 4 is dedicated to the biosynthesis and diversification of glycans, and the majority of human 5
proteins are thought to be post-translationally modified by glycans, a process known as 6 glycosylation (Apweiler et al., 1999; Varki and Marth, 1995) . Glycosylation can occur at several 7 amino acid residues, most commonly asparagines (N-linked) and serines or threonines (O-8 linked). As conjugates to proteins, glycans add an additional information layer and have direct 9 biological effects, ranging from stabilizing protein folds (Hebert et and there is growing interest in developing pharmaceutical agents that target these molecules 15 (Fuster and Esko, 2005) . However, while the functional importance of glycosylation is well 16 established, methods for mass-producing glycans and glycoconjugates are lagging (Sheridan, 17 2007; Walt et al., 2012) . Such technological gaps are to be expected in light of the immense 18 structural diversity and information density of glycans in nature (Werz et al., 2007) , which far 19 exceeds that of DNA or proteins. Unfortunately, this complexity, coupled with a scarcity of 20 materials, has hindered production of glycomolecules which in turn has limited the availability of 21 chemically defined oligosaccharides for use as standards in glycan structure determination 22 To furnish oligosaccharides for biological and structural studies, a variety of methods 1 have been described that enable laboratory preparation of these important compounds. One 2 such method involves the enzymatic or chemical deglycosylation of glycoproteins from natural 3 sources (e.g., hen egg yolk) followed by a series of purification steps (Kajihara et Solution-phase synthesis utilizes a one-pot strategy, wherein differences in the reactivity of 13 glycosyl donors allow for ligation in the proper oligosaccharide sequence. In solid-phase 14 synthesis, the reducing-end sugar is connected to a solid support and each additional sugar 15 residue is added sequentially, after which the glycan is cleaved from the resin. While recent 16 advances to these methods have greatly improved the number and diversity of glycans that can 17 be produced chemically, including the addition of non-natural residues, this approach remains 18 limited by the cost and scale of production (Blow, 2009 deglycosylation of these biosynthetic precursors, the microbially-derived oligosaccharides are 13 subjected to a greatly simplified purification scheme followed by structural remodeling using 14 GTs, including several from the mammalian glycosylation pathway that are not commercially 15 (Fig. 1a) , which was chosen as a vehicle to isolate 1 oligosaccharides because it has the highest glycan abundance of all known glycoproteins, and 2 is produced at high yields when expressed recombinantly in wild-type yeast strains. Invertase 3 carries high-mannose glycans comprised of eight or more mannose units (Trimble et Fig. S1a ). To determine whether it was 16 possible to trim these high-mannose glycans to the human-type Man 5 GlcNAc 2 , we subjected 17 released glycan 1 to a series of mannosidases and determined that the additional mannose 18 residues consisted of natural sources is the difficulty in purification. Therefore, a point of emphasis was to develop a 24 simplified purification method. After testing multiple separation techniques, we determined that 25 an initial silica column followed by a charcoal/celite with a single elution step, and a graphitized 26 carbon column with a gradient elution was the simplest method. This purification method 1 resulted in a product having >95% purity as assessed by mass spectrometry (MS) and nuclear 2 magnetic resonance (NMR) spectroscopy (Fig. 2a) . Isolation, mannose trimming, and 3 purification of the oligosaccharides from 1 g of invertase resulted in a yield of 0.7 mg of 4 as 4 determined by measuring dry weight and fluorophore-assisted carbohydrate electrophoresis 5 (FACE) analysis (Gao, 2005) (Fig. S1b) . A similar procedure yielded glycan 5 (Fig. S2a) . Thus, 6 we confirm that biosynthesis of S. cerevisiae invertase glycans provides a viable reservoir of 7 human-type oligosaccharide precursors. 8
As an alternative biosynthetic route to precursor glycans, we investigated the use of 9 glycoengineered E. coli as producers of the starting material for glycan diversification (Fig. 1b) . 10 Unlike all natural or engineered eukaryotic hosts, E. coli cells do not have native glycosylation 11 pathways nor is glycosylation an essential mechanism in this host. As a result, E. coli provides 12 an unformatted "operating system" that can be genetically reprogrammed to produce discrete, 13 uniform glycans that are not attached to undesired targets and do not cause problems with cell 14 physiology or morphology. Using natural pools of nucleotide sugars (e.g., UDP-GlcNAc, GDP-15 lipid extraction from E. coli followed by non-enzymatic removal of 2 from undecaprenol, resulting 20 in a structurally uniform Man 3 GlcNAc 2 glycoform (Fig. 2b) . It should be noted that addition of 21 yeast mannosyltransferase Alg11 to the synthetic glycosylation pathway resulted in formation of 22
Und-PP-linked 3 that could be similarly processed to generate nearly pure Man 5 GlcNAc 2 23 glycans (Fig. S2b) . Isolation of lipid-linked glycans from E. coli in this manner eliminates several 24 difficulties associated with purification and heterogeneity. Moreover, the short time requirements 25 and low costs associated with bacterial culture are advantageous for the synthesis of human-1 type N-glycan precursors. 2
Expression and purification of eukaryotic glycosyltransferases. A number of the 3 glycosylation enzymes that are natively involved in the early stages of remodeling oligomannose 4 glycan 4 are not commercially available, and methods to produce these enzymes have not been 5 reported. Therefore, we undertook the development of methods for recombinant expression and 6 purification of three N-acetylglucosaminyltransferases (GnTs), namely GnTI, GnTII, and GnTIV. 7
We chose E. coli due to its proven track record as a protein expression host. To promote 8 efficient folding in the cytoplasm, the genes encoding Nicotiana tabacum GnTI, Homo sapiens 9
GnTII, and Bos taurus GnTIV were all fused to the C-terminus of the gene encoding E. coli 10 maltose binding protein (MBP) lacking its native export signal. Both GnTI and GnTIV were 11 solubly expressed over a wide range of temperatures (15-37°C) and in a number of different E. 12 coli strain backgrounds (e.g., MC4100, SHuffle T7 Express, and Origami2(DE3)). In contrast, 13
GnTII was only expressed solubly at temperatures at or below 25°C and required a host strain 14 lacking both the thioredoxin reductase (trxB) and glutathione reductase (gor) genes (e.g., 15
Origami 2(DE3)), which greatly enhances disulfide bond formation in the E. coli cytoplasm 16 (Bessette et al., 1999) . All three enzymes were purified by amylose affinity chromatography and 17 retained as fusions to MBP for enzymatic remodeling of yeast-derived glycan 4 and bacteria-18 derived glycan 2 as described below. Fig. 3a) . Importantly, the chemical shifts of 6 synthesized herein matched previous NMR 1 characterization of this oligosaccharide structure ( Table 1 (Fig. 3b) . 5 Conducting multiple reactions in a single step eliminates purification of each intermediate, which 6 in turn reduces loss of product associated with purification. As an example of further elaboration 7 of these oligosaccharides, each glycan was treated with B. taurus β 1,4-galactosyltransferase to 8 produce glycans 8 and 9. Addition of galactose residues was confirmed by MS, and by the 9 appearance of a peak that corresponds to galactose in each NMR spectrum ( Fig. 3c and d) . In 10 the case of glycan 9, the reaction must be conducted in a two-step process to eliminate the 11 possibility of producing 8 as a side product. Taken together, these results confirm bioenzymatic 12 synthesis of human-type, hybrid oligosaccharides. 13
Bioenzymatic synthesis of hybrid and complex glycans from bacteria-derived precursor. 14 We next evaluated whether the E. coli-derived Man 3 GlcNAc 2 glycan 2 could be used as the 15 starting material for 200-µg pilot-scale synthesis of hybrid-and complex-type glycans. An 16 advantage of this precursor glycan is that it eliminates two mannosidase-catalyzed 17 deglycosylation steps required to produce the hybrid GlcNAcMan 3 GlcNAc 2 glycan 11. Indeed, 18
following treatment with MBP-GnTI, efficient transfer of a GlcNAc residue directly to the α 1,3 19 arm of 2 was observed (Fig. 4a) , despite the fact that this precursor glycan is not the native 20 substrate for this enzyme. The chemical shifts of glycan 11 were in agreement with previous 21 NMR spectroscopy of this oligosaccharide structure ( Table 1 ) (Kajihara et al., 2004) . Along 22 similar lines, we synthesized the human-type complex GlcNAc 2 Man 3 GlcNAc 2 glycan 14 using a 23 one-pot strategy whereby both MBP-GnTI and MBP-GnTII were added simultaneously to 2 (Fig.  24   4b) . This glycan was also characterized by NMR and matched previous characterization of this 25 oligosaccharide structure ( MBP-GnTIV to produce glycans 12 and 17, respectively, with β 1,4-GlcNAc branching ( Fig. 4c  4 and d, and Table 1 ). Interestingly, when carrying out the synthesis of glycan 17, the reaction 5 rate of GnTII was greatly decreased when acting on glycan 12 in the one-pot reaction. 6 Therefore, glycan 17 was synthesized in a stepwise fashion whereby a first reaction with MBP-7
GnTI and MBP-GnTII was followed by a second reaction with MBP-GnTIV. Glycans with
GlcNAc branching were achieved by step-wise treatment of 14 or 17 with H. sapiens GnTV to 9 yield 13 and 20, respectively ( Fig. 4e and f, and Table 1 ). Another interesting point is that two 10 pairs of the GlcNAc-terminal glycans 12 and 14, 13 and 17 are structural isomers, which would 11 be useful as standards for glycomics research and as affinity probes for determining lectin 12 substrate specificity. Collectively, these results demonstrate that treatment of the bacteria-13 derived precursor glycan with different combinations of GnTI, GnTII, GnTIV, and GnTV is an 14 efficient route to multiantennary, GlcNAc-terminal oligosaccharides. 15
Additional modification of select oligosaccharides described above was conducted to 16 demonstrate the rapid increase in the number of glycan structures that can be produced by our 17 bioenzymatic method. For example, H. sapiens GnTIII adds a bisecting GlcNAc to the β 1,4-18 mannose and is thought to be a natural regulator of branching, since attachment of this residue 19 eliminates further elaboration by GnTs. To generate such bisecting glycan structures, glycans 20 14 and 17 were synthesized in a first reaction and then, for reasons described above, treated in 21 a subsequent reaction with GnTIII to yield 18 and 21, respectively. Analysis of the reaction 22 products revealed that GnTIII installed branching GlcNAc residues at a high conversion rate 23
( Fig. 4g and h, and Table 1 ). The resulting bisecting GlcNAc structures, which supply additional 24 structural isomers to our panel, would be of particular interest for determining differences in 25 lectin binding specificity. Finally, galactose residues were successfully added to 11, 12, 14, and 26 β 1,4-galastosyltransferase, yielding glycans 10, 15, 19, and 16, 1 respectively ( Fig. 4i-l, and Table 1 ). While these latter reactions were only conducted on select 2 glycan structures with two different GTs, one could easily apply these GTs to each glycan 3 produced herein, resulting in an exponential increase in the number of oligosaccharides in the 4 glycan library. 5
Construction and evaluation of an N-glycan microarray. To demonstrate the functionality of 6 the glycan library, we developed microarrays using a novel bifunctional fluorescent linker, 2-7 amino-N-(2-aminoethyl)-benzamide (AEAB) (Song et al., 2009 ). Specifically, glycans 2-21 were 8 directly conjugated to AEAB through its arylamine group by reductive amination to form glycan-9 AEABs (GAEABs) and then purified by multidimensional HPLC. Following purification, GAEABs 10 were covalently immobilized onto N-hydroxysuccinimide (NHS)-activated glass slides via their 11 free alkylamine alongside the similarly immobilized reference compounds LNnT, LNT, and NA2 12 (Fig. 5a ), which were prepared from natural glycans as described previously (Song et al., 2009) . As many have argued (Walt et al., 2012) , the development of simple and cost-effective methods 2 to produce diverse glycomolecules is needed to meet the demand of, and grow, the 3 glycoscience community. In this work, we addressed this need with the demonstration of an 4 efficient new methodology -called bioenzymatic synthesis -that enables production of large 5 quantities of hybrid-and complex-type N-glycans. This was accomplished by first harnessing 6 the power of microbial biosynthesis to furnish a renewable reservoir of starting material. 7
Specifically, up to milligram amounts of precursor oligosaccharides were derived from either 8 wild-type yeast that recombinantly express hypermannosylated invertase or glycoengineered E. 9
coli that produce lipid-linked paucimannose glycans. In parallel, we developed simplified 10 methods to purify the resulting oligosaccharides, as well as robust expression and purification 11 methods for key glycan remodeling enzymes (e.g., eukaryotic GnTs) that are not commercially 12 available. Armed with these and other commercially available GTs, we efficiently transformed 13
precursor oligosaccharides into a library of hybrid and complex N-glycans including asymmetric 14 multi-antennary structures, all in appreciable yields and without the need of a specialized 15 skillset. We anticipate that this technology will help to overcome many of the critical barriers to 16 glycan production by offering a user-friendly synthesis methodology that can reliably deliver 17 homogeneous glycans from a consistent source and flexibly adapt to production needs. Genetic Stock Center (CGSC). The resulting phage was used to infect Origami2(DE3) target 6 cells and successful transductants were selected on LB plates supplemented with kanamycin 7 (Kan). The Kan resistance cassette was subsequently removed by transforming the resulting 8 strain with plasmid pCP20 as described (Datsenko and Wanner, 2000) . This resulted in 9 generation of strain Origami2(DE3) Δ nanA. Subsequent deletion of the waaL (rfaL) and gmd 10 genes was performed in the same manner using donor strains JW3597-1 (ΔrfaL734::kan) and 11 JW2038-1 (Δgmd751::kan). Yeast strain FY834 was used for homologous recombination using 12 plasmid pMQ70 as described previously (Shanks et al., 2006) . YPD growth medium was used 13 to maintain yeast and synthetic defined uracil dropout medium was used to select and maintain 14 yeast with plasmids. Plasmid pYCG was used for production of lipid-linked Man 3 GlcNAc 2 and 15 has been described previously (Valderrama-Rincon et al., 2012). A second plasmid containing 16 the E. coli manB and manC genes for over-production of GDP-mannose was produced using 17 homologous recombination in S. cerevisiae (Shanks et al., 2006) . Briefly, genes encoding 18 phosphomannomutase (ManB) and mannose-1-phosphate guanylyltransferase (ManC) were 19 PCR-amplified from E. coli genomic DNA using primer pairs that contained the priming region 20 for the manB and manC genes, respectively, along with 40-bp overhangs of pMQ70. The 21 resulting PCR products and the linearized pMQ70 plasmid were used to transform yeast strain 22 FY834, yielding plasmid pManCB. Constructs assembled in yeast were electroporated into E. 23 coli MC4100 for verification via PCR, restriction enzyme digestion, and/or sequencing. For 24 expression of eukaryotic GnTs, N. tabacum GnTI, H. sapiens GnTII, B. taurus GnTIV were all 25 cloned for expression as C-terminal fusions to E. coli MBP lacking its native export signal 26 peptide. Briefly, genes encoding MBP and the respective GnT enzyme were amplified with 1 primers containing regions of overlap to the fusion partner and pMQ70 plasmid. The PCR 2 products were assembled with linearized pMQ70 by homologous recombination as described 3 above, yielding plasmids pMBP-GnTI, pMBP-GnTII, and pMBP-GnTIV. 4 The cells were then pelleted by centrifugation at 4,236 x g, resuspended in 5 mL of methanol, 11
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and sonicated five times at 10-sec pulses. The sonicated lysate was then poured into a glass 12 petri dish and heated at 60°C until dry. The methods for extraction of LLOs and release of the 13 glycan from the lipid were followed as described in Gao et al. (Gao, 2005) . Briefly, E. coli cell 14 pellets were resuspended in 2:1 chloroform:methanol, sonicated, and the remaining solids 15 collected by centrifugation. This pellet was sonicated in water and collected by centrifugation. 16 The resulting pellet was sonicated in 10:10:3 chloroform:methanol:water to isolate the LLOs 17 from the inner membrane. The LLOs were purified using acetate-converted DEAE anion 18 exchange chromatography as they bind to the anion exchange resin via the phosphates that link 19 the lipid and glycan. The resulting compound was dried and treated by mild acid hydrolysis to 20 release glycans from the lipids. The released glycans were then separated from the lipid by a 21 1:1 butanol:water extraction, wherein the water layer contains the glycans. The glycans were 22 then further purified with a graphitized carbon column using a 0-50% water:acetonitrile gradient. Synthesis of hybrid oligosaccharides from the yeast-derived precursor. To produce 6, a 12 500-µg sample of 4 was treated with an excess amount of GnTI and UDP-GlcNAc (Sigma-13 Aldrich) in GnT buffer (20 mM HEPES, 50 mM NaCl, 10 mM MnSO 4 , pH 7.2), and incubated at 14 37°C until the reaction was complete, as determined by MS. To synthesize 7, a 500-µg sample 15 of 4 was treated with an excess amount of GnTI and GnTIV along with an excess of UDP-16
GlcNAc and incubated at 37°C until the reaction was complete. Each glycan was desalted as 17 Both UDP-GlcNAc and UDP-Gal were added in 3-fold molar excess, and each enzyme was also 1 added in excess as determined empirically. All synthesized glycans were desalted as described 2 above and purified by graphitized carbon using a 0-50% acetonitrile:water gradient. The purified 3 products were analyzed by MALDI-TOF MS, FACE, and 600-MHz 1 H NMR. 4
Synthesis of GlcNAc terminal glycans. To produce glycan 11, Man 3 GlcNAc 2 was treated with 5
GnTI and incubated overnight at 37°C. To produce 14, both GnTI and GnTII were added 6 simultaneously to 2 in GnT buffer and incubated overnight at 37°C. To synthesize 12, GnTI and 7
GnTIV were added simultaneously to 2 in GnT buffer and incubated overnight at 37°C. For 8 synthesis of 13, GnTI, GnTIV, and H. sapiens GnTV (R&D systems) were added simultaneously 9 to 2 in GnTI buffer and incubated at 37°C until the reaction was complete. To synthesize 17, 10
GnTI and GnTII were added simultaneously to 2 in GnT buffer and incubated at 37°C until the 11 reaction was complete. GnTIV was then added to the solution and incubated at 37°C until the 12 reaction was complete. Similarly, 20 was synthesized by adding GnTI and GnTII to 2 in GnT 13 buffer and incubated at 37°C until the reaction was complete. GnTIV and GnTV were then 14 added to the solution and incubated at 37°C until the reaction was complete. The progress of 15 each reaction was monitored by MALDI-TOF MS and determined to be complete when the 16 substrate glycan was undetectable. 17
Synthesis of bisecting GlcNAc glycans. To produce 18 and 21, the glycans 14 and 17 were 18 first synthesized as described above, and used as substrates for the addition of bisecting 19
GlcNAc. H. sapiens GnTIII (R&D systems) was added to 14 and 17 separately in GnT buffer 20 and incubated at 37°C until the reaction was complete, as determined by MS. 21
Synthesis of Gal terminal glycans. For synthesis of 10, GnTI and GalT were added 22 simultaneously to 2 in GnTI buffer and incubated at 37°C until the reaction was complete. For 23 synthesis of 15, 16, and 19, the GlcNAc terminal glycans (12, 14, 17) were first synthesized as 24 described above before the addition of Gal to avoid production of 10 as a side product. GalT zTOCSY, and 2D-HSQC were also acquired as needed) spectra were obtained at 25°C on 7
Varian Inova 600 MHz spectrometer equipped with cryoprobe using standard Varian pulse 8 sequences. Glycans 4, and 6-9 (≥100 μ g each) were prepared as above, except rotary 9 evaporation was used for deuterium exchange (D 2 O, 99,9%, Sigma), and 1-D proton spectra 10 were acquired at 25°C using a Varian Inova 600-MHz spectrometer (Cornell University) with a 11 pulse field gradient probe. Chemical shifts were measured relative to HOD peak (δ H =4.82 ppm). 12
Glycan-AEAB conjugation and purification. Free reducing glycans were conjugated with 13 water, loaded onto the -NH 2 SPE column, which had been prewashed with acetonitrile, water 24 and 85% acetonitrile in water. The -NH 2 SPE column was then washed with 3 bed volumes of 25 acetonitrile, followed by 3 bed volumes of 85% acetonitrile and the AEAB conjugate was eluted 1 by 5% MeCN, 100 mM ammonium acetate. The combined eluents were dried under vacuum to 2 remove the acetonitrile and lyophilized repeatedly to remove the ammonium acetate. 3
Printing, binding assay, and scanning. NHS-activated slides were purchased from Schott 4 (Louisville, KY). Non-contact printing was performed using a Scienion printer. The printing, 5 binding assay, and scanning conditions were essentially the same as described previously 6 (Song et al., 2011) . Briefly, all samples were printed at 100 
